137 related articles for article (PubMed ID: 19169880)
1. Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species.
Haznedar JO; Patyna S; Bello CL; Peng GW; Speed W; Yu X; Zhang Q; Sukbuntherng J; Sweeny DJ; Antonian L; Wu EY
Cancer Chemother Pharmacol; 2009 Sep; 64(4):691-706. PubMed ID: 19169880
[TBL] [Abstract][Full Text] [Related]
2. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients.
Houk BE; Bello CL; Kang D; Amantea M
Clin Cancer Res; 2009 Apr; 15(7):2497-506. PubMed ID: 19258444
[TBL] [Abstract][Full Text] [Related]
3. The influence of the time-of-day administration of the drug on the pharmacokinetics of sunitinib in rabbits.
Szałek E; Karbownik A; Sobańska K; Połom W; Grabowski T; Wolc A; Matuszewski M; Grześkowiak E
Eur Rev Med Pharmacol Sci; 2014 Aug; 18(16):2393-9. PubMed ID: 25219843
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of sunitinib in combination with fluoroquinolones in rabbit model.
Szałek E; Karbownik A; Grabowski T; Sobańska K; Wolc A; Grześkowiak E
Pharmacol Rep; 2013; 65(5):1383-90. PubMed ID: 24399735
[TBL] [Abstract][Full Text] [Related]
5. Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence.
Kloth JS; Binkhorst L; de Wit AS; de Bruijn P; Hamberg P; Lam MH; Burger H; Chaves I; Wiemer EA; van der Horst GT; Mathijssen RH
Clin Pharmacokinet; 2015 Aug; 54(8):851-8. PubMed ID: 25647628
[TBL] [Abstract][Full Text] [Related]
6. A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma.
Etienne-Grimaldi MC; Renée N; Izzedine H; Milano G
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Nov; 877(29):3757-61. PubMed ID: 19797000
[TBL] [Abstract][Full Text] [Related]
7. Nonclinical safety evaluation of sunitinib: a potent inhibitor of VEGF, PDGF, KIT, FLT3, and RET receptors.
Patyna S; Arrigoni C; Terron A; Kim TW; Heward JK; Vonderfecht SL; Denlinger R; Turnquist SE; Evering W
Toxicol Pathol; 2008 Dec; 36(7):905-16. PubMed ID: 18981453
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans.
Speed B; Bu HZ; Pool WF; Peng GW; Wu EY; Patyna S; Bello C; Kang P
Drug Metab Dispos; 2012 Mar; 40(3):539-55. PubMed ID: 22180047
[TBL] [Abstract][Full Text] [Related]
9. Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study.
Cabel L; Blanchet B; Thomas-Schoemann A; Huillard O; Bellesoeur A; Cessot A; Giroux J; Boudou-Rouquette P; Coriat R; Vidal M; Saidu NEB; Golmard L; Alexandre J; Goldwasser F
Fundam Clin Pharmacol; 2018 Feb; 32(1):98-107. PubMed ID: 29055166
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma.
Blanchet B; Saboureau C; Benichou AS; Billemont B; Taieb F; Ropert S; Dauphin A; Goldwasser F; Tod M
Clin Chim Acta; 2009 Jun; 404(2):134-9. PubMed ID: 19341717
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib in combination with clarithromycin or azithromycin - is there a risk of interaction or not?
Szałek E; Karbownik A; Połom W; Matuszewski M; Sobańska K; Urjasz H; Grabowski T; Wolc A; Grześkowiak E
Pharmacol Rep; 2012; 64(6):1554-9. PubMed ID: 23406766
[TBL] [Abstract][Full Text] [Related]
12. Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer.
Diekstra MH; Fritsch A; Kanefendt F; Swen JJ; Moes D; Sörgel F; Kinzig M; Stelzer C; Schindele D; Gauler T; Hauser S; Houtsma D; Roessler M; Moritz B; Mross K; Bergmann L; Oosterwijk E; Kiemeney LA; Guchelaar HJ; Jaehde U
CPT Pharmacometrics Syst Pharmacol; 2017 Sep; 6(9):604-613. PubMed ID: 28571114
[TBL] [Abstract][Full Text] [Related]
13. Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry.
de Bruijn P; Sleijfer S; Lam MH; Mathijssen RH; Wiemer EA; Loos WJ
J Pharm Biomed Anal; 2010 Mar; 51(4):934-41. PubMed ID: 19931354
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.
Lankheet NA; Kloth JS; Gadellaa-van Hooijdonk CG; Cirkel GA; Mathijssen RH; Lolkema MP; Schellens JH; Voest EE; Sleijfer S; de Jonge MJ; Haanen JB; Beijnen JH; Huitema AD; Steeghs N
Br J Cancer; 2014 May; 110(10):2441-9. PubMed ID: 24736581
[TBL] [Abstract][Full Text] [Related]
15. Characterization of preclinical in vitro and in vivo pharmacokinetics properties for KBP-7018, a new tyrosine kinase inhibitor candidate for treatment of idiopathic pulmonary fibrosis.
Huang Z; Li H; Zhang Q; Tan X; Lu F; Liu H; Li S
Drug Des Devel Ther; 2015; 9():4319-28. PubMed ID: 26273193
[TBL] [Abstract][Full Text] [Related]
16. Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662.
Yu H; Steeghs N; Kloth JS; de Wit D; van Hasselt JG; van Erp NP; Beijnen JH; Schellens JH; Mathijssen RH; Huitema AD
Br J Clin Pharmacol; 2015 May; 79(5):809-19. PubMed ID: 25393890
[TBL] [Abstract][Full Text] [Related]
17. Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study.
DuBois SG; Shusterman S; Reid JM; Ingle AM; Ahern CH; Baruchel S; Glade-Bender J; Ivy P; Adamson PC; Blaney SM
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1021-7. PubMed ID: 22179104
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the safety and pharmacokinetics of the multi-targeted receptor tyrosine kinase inhibitor sunitinib during embryo-fetal development in rats and rabbits.
Patyna S; Haznedar J; Morris D; Freshwater K; Peng G; Sukbuntherng J; Chmielewski G; Matsumoto D
Birth Defects Res B Dev Reprod Toxicol; 2009 Jun; 86(3):204-13. PubMed ID: 19294680
[TBL] [Abstract][Full Text] [Related]
19. Quantitation of unbound sunitinib and its metabolite N-desethyl sunitinib (SU12662) in human plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study.
Rais R; Zhao M; He P; Xu L; Deeken JF; Rudek MA
Biomed Chromatogr; 2012 Nov; 26(11):1315-24. PubMed ID: 22259028
[TBL] [Abstract][Full Text] [Related]
20. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period.
Britten CD; Kabbinavar F; Hecht JR; Bello CL; Li J; Baum C; Slamon D
Cancer Chemother Pharmacol; 2008 Mar; 61(3):515-24. PubMed ID: 17505827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
